Volume 143, Issue 3, Pages e5 (September 2012)

Slides:

Advertisements

Similar presentations

Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir (BOC) Plus PEGINTRON (PegInterferon Alfa-2b) and.

Advertisements

HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re-

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Triple Therapy Today: Phase III Results in G1 Relapsers and Nonresponders Bruce R. Bacon, M.D. James F. King MD Endowed Chair in Gastroenterology Professor.

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.

Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.

36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis.

Volume 16, Issue 6, Pages (September 2013)

Volume 149, Issue 6, Pages (November 2015)

Volume 146, Issue 2, Pages e6 (February 2014)

Volume 139, Issue 4, Pages (October 2010)

Volume 139, Issue 5, Pages e1 (November 2010)

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Boceprevir in Treatment Naive SPRINT-2

Volume 131, Issue 2, Pages (August 2006)

Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L

Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers Thilo Rattay, Ian P. Dumont, Hauke.

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Volume 139, Issue 4, Pages (October 2010)

Volume 153, Issue 4, Pages (October 2017)

Volume 139, Issue 1, Pages e18 (July 2010)

Volume 143, Issue 3, Pages e5 (September 2012)

Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in.

Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Volume 149, Issue 4, Pages e1 (October 2015)

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Volume 141, Issue 3, Pages e1 (September 2011)

Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz,

Volume 142, Issue 4, Pages (April 2012)

Volume 154, Issue 4, Pages (March 2018)

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome Onur Keskin, Heiner Wedemeyer, Ali Tüzün, Kalliopi.

Volume 141, Issue 5, Pages (November 2011)

Volume 146, Issue 2, Pages e6 (February 2014)

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening Brianna L. Norton,

Volume 146, Issue 7, Pages e3 (June 2014)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 152, Issue 1, Pages e4 (January 2017)

Volume 138, Issue 1, Pages (January 2010)

Volume 143, Issue 5, Pages e6 (November 2012)

A. Sidney Barritt, Michael W. Fried Gastroenterology

Volume 145, Issue 5, Pages e5 (November 2013)

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir Zobair.

Impact of New Hepatitis C Treatments in Different Regions of the World

Volume 142, Issue 6, Pages (May 2012)

Volume 138, Issue 1, Pages e2 (January 2010)

Rafael Esteban, Maria Buti Gastroenterology

Volume 140, Issue 7, Pages (June 2011)

Volume 145, Issue 4, Pages e3 (October 2013)

Covering the Cover Gastroenterology

Lisa I. Backus, Derek B. Boothroyd, Barbara R

Volume 132, Issue 1, Pages 5-6 (January 2007)

Genetic Factors and Hepatitis C Virus Infection

Volume 141, Issue 6, Pages (December 2011)

Volume 139, Issue 6, Pages (December 2010)

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Volume 136, Issue 5, Pages e2 (May 2009)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Christos Konstantakis, Maria Karamesini, Christos Triantos

Volume 147, Issue 2, Pages e1 (August 2014)

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Volume 139, Issue 5, Pages (November 2010)

Volume 147, Issue 6, Pages (December 2014)

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Presentation transcript:

Volume 143, Issue 3, Pages 608-618.e5 (September 2012) Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir Fred Poordad, Jean–Pierre Bronowicki, Stuart C. Gordon, Stefan Zeuzem, Ira M. Jacobson, Mark S. Sulkowski, Thierry Poynard, Timothy R. Morgan, Cliona Molony, Lisa D. Pedicone, Heather L. Sings, Margaret H. Burroughs, Vilma Sniukiene, Navdeep Boparai, Venkata S. Goteti, Clifford A. Brass, Janice K. Albrecht, Bruce R. Bacon Gastroenterology Volume 143, Issue 3, Pages 608-618.e5 (September 2012) DOI: 10.1053/j.gastro.2012.05.011 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 SVR by IL-28B rs12979860 genotype for (A) previously untreated patients (SPRINT-2) and (B) previous treatment-failure patients (RESPOND-2). BOC, boceprevir. Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 Median reductions in viral load from baseline on the basis of rs12979860 IL-28B genotype for (A) previously untreated patients (SPRINT-2) and (B) previous treatment-failure patients (RESPOND-2). Bars represent 25th and 75th percentiles. BOC, boceprevir. Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 SVR by IL-28B rs12979860 genotype and HCV-RNA level at week 4 and by HCV-RNA detectability at week 8 for (A and B) previously untreated patients (SPRINT-2) and (C and D) previous treatment-failure patients (RESPOND-2). Patients with missing data at week 4 or week 8 are not included. BOC, boceprevir. Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 Sustained virologic response in patients with poor response to interferon (<1 log10 decline in HCV RNA after a 4-week peginterferon-ribavirin lead-in) based on treatment week 8 response (log decline in viral load compared with baseline viral load, BOC RGT and BOC/PR48 arms combined). BOC, boceprevir. Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 1 Study design of SPRINT-2 and RESPOND-2.10,11 Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 2 Analysis populations for IL-28B rs12979860 genomic distribution for SPRINT-2 (A) and RESPOND-2 (B). BOC, boceprevir. Gastroenterology 2012 143, 608-618.e5DOI: (10.1053/j.gastro.2012.05.011) Copyright © 2012 AGA Institute Terms and Conditions